AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

10.97

+0.61 (5.89%)

At close: Aug 13, 2026, 4:00 PM EDT

10.96

-0.01 (-0.09%)

After-hours: Aug 13, 2026, 7:59 PM EDT

AbCellera Biologics Operating Metrics

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Programs Under Contract	-	-	-	-	-	739.00	710.00	692.00	679.00	660.00	642.00	633.00	607.00
Programs Under Contract Growth	-	-	-	-	-	11.97%	10.59%	9.32%	11.86%	16.20%	24.66%	39.43%	54.85%
Partnered Program Starts	-	-	-	-	-	404.00	392.00	374.00	356.00	339.00	342.00	319.00	291.00
Partnered Program Starts Growth	-	-	-	-	-	19.17%	14.62%	17.24%	22.34%	29.89%	45.53%	47.00%	41.95%
Number of Discovery Partners	-	-	-	-	-	170.00	164.00	160.00	157.00	152.00	148.00	145.00	140.00
Number of Discovery Partners Growth	-	-	-	-	-	11.84%	10.81%	10.34%	12.14%	14.29%	19.35%	26.09%	30.84%
Number of Molecules in the Clinic	60.00	57.00	54.00	50.00	45.00	41.00	36.00	33.00
Number of Molecules in the Clinic Growth	33.33%	39.02%	50.00%	51.52%	50.00%	51.85%	50.00%	50.00%

Revenue by Segment

Period Ending	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Licensing	36.65M	46.94M	46.92M	11.03M	11.11M	1.04M	1.05M	953.00K
Licensing Growth	229.84%	4,431.27%	4,372.83%	1,057.50%	1,106.41%	33.33%	8.26%	0.53%
Research Fees	28.53M	31.26M	27.21M	24.29M	21.76M	20.58M	26.28M	30.26M
Research Fees Growth	31.07%	51.93%	3.52%	-19.72%	-28.37%	-40.80%	-26.08%	-20.86%
Milestone Payments	1.00M	1.00M	1.00M	-	-	1.50M	1.50M	1.75M
Milestone Payments Growth	-	-33.33%	-33.33%	-	-	500.00%	-	-